<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hepatic sinusoidal injury arises occasionally after <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>As a result, <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> associated with <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> occurs in some cases </plain></SENT>
<SENT sid="2" pm="."><plain>We report two cases of advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> which showed <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> after administration of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>In both cases, mFOLFOX6/bevacizumab was administered as a firstline chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Splenic volume was determined by loading the CT images onto a commercially available workstation </plain></SENT>
<SENT sid="5" pm="."><plain>In case 1, initial splenic volume was 137.82mL </plain></SENT>
<SENT sid="6" pm="."><plain>Two months later, it increased to 160.96mL </plain></SENT>
<SENT sid="7" pm="."><plain>After six cycles of chemotherapy, we removed <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> due to <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Consequently, the splenic volume decreased to 151.58mL </plain></SENT>
<SENT sid="9" pm="."><plain>Subsequent to the reintroduction of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, the splenic volume increased to 177.48mL </plain></SENT>
<SENT sid="10" pm="."><plain>Following two cycles of mFOLFOX6/bevacizumab, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> was removed again </plain></SENT>
<SENT sid="11" pm="."><plain>In a similar way, splenic volume decreased to 158.52mL </plain></SENT>
<SENT sid="12" pm="."><plain>In case 2, initial splenic volume was 105.84mL </plain></SENT>
<SENT sid="13" pm="."><plain>Ten months later, it increased to 228.54mL </plain></SENT>
<SENT sid="14" pm="."><plain>After administration of mFOLFOX6/bevacizumab, we continued chemotherapy with sLV5FU2/bevacizumab and irinotecan </plain></SENT>
<SENT sid="15" pm="."><plain>The splenic volume decreased to 197 </plain></SENT>
<SENT sid="16" pm="."><plain>06mL </plain></SENT>
<SENT sid="17" pm="."><plain>In conclusion, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>- based chemotherapy induces an increase in splenic volume, however, it may be reversible after discontinuation of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
</text></document>